DeDora Capital Inc. Buys 165 Shares of Amgen Inc. (NASDAQ:AMGN)

DeDora Capital Inc. raised its stake in Amgen Inc. (NASDAQ:AMGN) by 3.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 5,601 shares of the medical research company’s stock after purchasing an additional 165 shares during the quarter. DeDora Capital Inc.’s holdings in Amgen were worth $1,460,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Capital Performance Advisors LLP bought a new position in shares of Amgen during the third quarter valued at approximately $25,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen during the third quarter valued at approximately $29,000. Heck Capital Advisors LLC bought a new position in shares of Amgen during the fourth quarter valued at approximately $36,000. Livelsberger Financial Advisory bought a new position in shares of Amgen during the third quarter valued at approximately $56,000. Finally, Kennebec Savings Bank bought a new position in shares of Amgen during the third quarter valued at approximately $57,000. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other Amgen news, EVP Murdo Gordon sold 8,771 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total value of $2,585,603.09. Following the transaction, the executive vice president now owns 44,186 shares of the company’s stock, valued at approximately $13,025,590.94. This represents a 16.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 35,405 shares of company stock valued at $10,410,596. 0.69% of the stock is owned by company insiders.

Amgen Trading Down 2.0 %

Amgen stock opened at $291.16 on Friday. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.96. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The stock has a market capitalization of $156.51 billion, a PE ratio of 38.56, a price-to-earnings-growth ratio of 3.01 and a beta of 0.56. The business’s fifty day moving average is $273.75 and its 200 day moving average is $302.14.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, sell-side analysts predict that Amgen Inc. will post 20.59 EPS for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a $2.38 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.27%. Amgen’s dividend payout ratio is currently 126.09%.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of recent analyst reports. UBS Group decreased their target price on Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a report on Thursday, October 31st. Truist Financial reduced their price target on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research note on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reduced their price target on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Wolfe Research started coverage on Amgen in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 price target on shares of Amgen in a research note on Tuesday, October 22nd. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $314.09.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.